QCG
AVIR icon

Quadrant Capital Group’s Atea Pharmaceuticals AVIR Stock Holding History

Quadrant Capital Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-319
Closed -$1.29K – 2708
2024
Q1 		$1.29K Buy
+319
New +$1.25K ﹤0.01% 2559
2023
Q2 		– Sell
-58
Closed -$195 – 2693
2023
Q1 		$195 Buy
+58
New +$235 ﹤0.01% 2676
2022
Q4 		– Sell
-87
Closed – – 2742
2022
Q3 		$0 Sell
87
-43
-33% -$329 ﹤0.01% 2636
2022
Q2 		$1K Buy
+130
New +$887 ﹤0.01% 2320
2022
Q1 		– Sell
-46
Closed – – 2497
2021
Q4 		$0 Buy
46
+22
+92% +$343 ﹤0.01% 2506
2021
Q3 		$1K Buy
+24
New +$666 ﹤0.01% 2245

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Quadrant Capital Group's AVIR Position: Q2 2024 in Review

Quadrant Capital Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 319 shares — an estimated $1.29K sold.

Quadrant Capital Group first reported a position in AVIR in Q3 2021 and held it in 6 quarters. The position peaked at $1.29K in Q1 2024. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • Quadrant Capital Group reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 319 Atea Pharmaceuticals shares in Q2 2024, an estimated $1.29K.
  • Quadrant Capital Group first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Quadrant Capital Group's Atea Pharmaceuticals position peaked at $1.29K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Quadrant Capital Group's 13F filing for Q2 2024, filed 12 Aug 2024.